

 Early Warning System

EIB-20240118

GVM ADVANCED MEDICAL DEVICES RDI



Quick Facts

Countries	Italy
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-12-19
Borrower	GRUPPO VILLA MARIA SPA
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 36.28 million
Project Cost (USD)	\$ 84.99 million



Project Description

According to the Bank's website, the project supports the promoter's investments in (i) research, development and manufacturing capabilities for medical devices in the cardiovascular and respiratory therapeutic areas, (ii) clinical and translational research for cardiovascular and metabolic diseases and (iii) digitalisation of its healthcare infrastructures across Europe over the period 2024-2027.

- i) The operation supports both the development of medical devices, carried out by a subsidiary of the Borrower, as well as early-stage, clinical and translational research conducted by the Promoter across its network of hospitals and healthcare facilities.
- ii) It will also finance the construction of a new manufacturing facility for cardio-pulmonary medical devices, as an extension of the Promoter's already existing production site, to increase its industrial footprint and know-how.
- iii) Lastly, the EIB will support digital initiatives to be undertaken by the Promoter across its extensive network of healthcare facilities and operations in the period 2024-2027, to increase digitalisation in the European healthcare sector.



Early Warning System Project Analysis

The project concerns investments in R&D and digitalisation, for which significant environmental and social effects are not expected. Moreover, the Project supports the construction of a manufacturing facility, as an extension to the existing production plant of the Promoter, in relation to the development and manufacturing of medical devices. According to Annex 3 of Italian law No. 152/2006 (and its subsequent amendments) transposing the Environmental Impact Assessment (EIA) Directive 2011/92/EU amended by 2014/52/EU, the construction of the new manufacturing facility for medical devices is not subject to an EIA procedure.



Investment Description

- European Investment Bank (EIB)

The financing is backed by InvestEU, the European Union's investment programme.



Private Actors Description

The *GVM* group was founded and is led by Ettore Sansavini. It operates in the health, research, biomedical and thermal care sectors, with a particular focus on specialist care, medical prevention and promoting well-being and quality of life. At the heart of GVM is their integrated network of 29 hospitals – many of which are highly specialised – four health centres and three care homes spread over 11 regions in Italy. These regions are: Piedmont, Lombardy, Liguria, Veneto, Emilia-Romagna, Tuscany, Lazio, Puglia, Marche, Campania and Sicily. GVM also operates in other countries, with 15 hospitals in France, Poland, Albania, Ukraine and Kosovo. GVM spa is headquartered in Lugo, in the province of Ravenna.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	GVM Care & Research S.p.A.	Client	-



Contact Information

Contact: Lorenzo Squintani

Email: l.squintani@eib.org

Phone: +352437982528

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - GVM ADVANCED MEDICAL DEVICES RDI](#)

Media

- [Italy: InvestEU - EIB provides €35 million in financing to GVM Group to support research, technology](#)



Other Related Projects

- EIB-20220093 PAN-EUROPEAN INNOVATION LENDING ENVELOPE I